Filtered By:
Vaccination: Influenza Vaccine
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 427 results found since Jan 2013.
Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
CONCLUSION: The investigational QIV was immunogenic with an acceptable safety profile in children 6 months to 8 years of age.
CLINICAL TRIAL REGISTRATION: NCT03336593.
PMID: 31862195 [PubMed - as supplied by publisher]
Source: Vaccine - December 16, 2019 Category: Allergy & Immunology Authors: Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, Sari RM, Bachtiar NS, Rusmil K, Kartasasmita CB Tags: Vaccine Source Type: research
Brand-Specific Enhanced Safety Surveillance of GSK ’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season
ConclusionIn compliance with EMA guidance, this study design allowed for near real-time assessment of AEs. No safety signals were detected at any point during the study period. The study supports and confirms the acceptable safety profile of GSK ’s IIV4.ClinicalTrials.gov identifierNCT03688620.
Source: Drug Safety - December 27, 2019 Category: Drugs & Pharmacology Source Type: research
Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
CONCLUSIONS: The immunogenicity of QIV for common ingredients was similar to that of TIV, but the former exhibited significantly higher immunogenicity for the unique lineage. QIV also had the same reliable safety as TIV.
PMID: 31948819 [PubMed - as supplied by publisher]
Source: Vaccine - January 12, 2020 Category: Allergy & Immunology Authors: Huang C, Fu X, Zhou Y, Mi F, Tian G, Liu X, Wu J, Ding C, Yan D, Li L, Yang S Tags: Vaccine Source Type: research
Coronavirus: What parents should know and do
As a parent, you can’t help but worry about the safety of your children. So it’s natural that as stories about the novel coronavirus that started in China flood the news, parents worry about whether their children could be at risk.
We are still learning about this new virus; there is much we do not know yet about how it spreads, how serious it can be, or how to treat it. The fact that so much is unknown is a big part of what makes it frightening. But there are things we do know — about this virus and other similar viruses — that can help us keep our children safe and well.
All of the advice below assumes that you a...
Source: Harvard Health Blog - February 5, 2020 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Adolescent health Children's Health Infectious diseases Parenting Source Type: blogs
Post #47 How to Optimally Utilize Tamiflu
Every year in the United States, the CDC estimates that influenza results in between 9 million – 45 million illnesses, between 140,000 – 810,000 hospitalizations, and between 12,000 – 61,000 deaths (approximately 100 – 200 being pediatric fatalities). In the United States, the immense disease burden of the flu is unparalleled with any other pathogen, but fortunately there is a vaccine and antiviral medications which help to mitigate the yearly morbidity and mortality wrought by influenza.Because the flu changes its shape every year by a process called antigenic shift and drift, i...
Source: A Pediatrician's Blog - February 22, 2020 Category: Pediatrics Source Type: blogs
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
The False Choice Between Science And Economics
This article originally appeared on The Bulwark here.
The post The False Choice Between Science And Economics appeared first on The Health Care Blog.
Source: The Health Care Blog - May 1, 2020 Category: Consumer Health News Authors: Christina Liu Tags: COVID-19 Health Policy David Shaywitz Source Type: blogs
Fight Aging! Newsletter, May 4th 2020
The objective is to start treating chronic diseases from the root and not the symptoms of the disease. As we are starting to enroll patients in "senolytics-clinical trials," it will be imperative to assess if senolysis efficiently targets the primary cause of disease or if it works best in combination with other drugs. Additional basic science research is required to address the fundamental role of senescent cells, especially in the established contexts of disease.
Notes on Self-Experimentation with Sex Steroid Ablation for Regrowth of the Thymus
https://www.fightaging.org/archives/2020/04/notes-on-self-experim...
Source: Fight Aging! - May 3, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
CONCLUSIONS: Self-reported AEFI rates did not differ by trimester (IIV), or by vaccine brand (IIV or dTpa). Concomitant influenza and pertussis vaccination was associated with more frequent, but low rates of minor, expected AEFI. These real world 'citizen science-based' data provide further reassuring evidence of the safety of maternal vaccination.
PMID: 32499067 [PubMed - as supplied by publisher]
Source: Vaccine - May 31, 2020 Category: Allergy & Immunology Authors: Glover C, Crawford N, Leeb A, Wood N, Macartney K Tags: Vaccine Source Type: research
Patchless administration of canine influenza vaccine on dog's ear using insertion-responsive microneedles (IRMN) without removal of hair and its in vivo efficacy evaluation.
Abstract
Microneedles provide the advantages of convenience and compliance by avoiding the pain and fear of needles that animals often experience. Insertion-responsive microneedles (IRMN) were used for administration to a hairy dog without removing the dog's hair. Canine H3N2 vaccine was administered with IRMN attached to the dog's ears ex vivo and the conventional microneedle system (MN) was administered for 15 min to compare puncture performance and delivery efficiency. The vaccine was also administered to compare antibody formation using IRMN with the use of intramuscular injection. The veterinarian observed th...
Source: European Journal of Pharmaceutics and Biopharmaceutics - June 12, 2020 Category: Drugs & Pharmacology Authors: Choi IJ, Na W, Kang A, Ahn MH, Yeom M, Kim HO, Lim JW, Choi SO, Baek SK, Song D, Park JH Tags: Eur J Pharm Biopharm Source Type: research
High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
Conclusion: HD-IIV4 has proven immunogenic, safe, and effective in preventing influenza in older adults and should be recommended as the vaccine of choice in this patient population.
PMID: 32578447 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 23, 2020 Category: Drugs & Pharmacology Authors: Chahine EB Tags: Ann Pharmacother Source Type: research
Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the unders...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
A Randomized Controlled Trial of NSAIDS or Exercise to Reduce Delayed Local Pain after Influenza Vaccination
Publication date: Available online 12 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Laurie A. Housel, Thomas A. Beltran, Christina Spooner, Limone C. Collins, Daniel F. Ewing, Maya Williams, Bruce M. McClenathan
Source: The Journal of Allergy and Clinical Immunology: In Practice - September 14, 2020 Category: Allergy & Immunology Source Type: research
Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease.
CONCLUSION: Simultaneous inoculations of TIV and PPSV23 were safety in patients with CAD, suggesting that dual vaccinations can be considered even in patients with CAD.
PMID: 33055462 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - October 21, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
